Introduction
============

Heart failure is a growing problem with an increasing number of affected people and with an increasing burden on society ([@b24]). Much has been done to improve survival in patients with heart failure. The first breakthrough came with the VHEFT-1 (Vasodilator Heart Failure Trial) trial where it was demonstrated that a combination of hydralazine and isosorbide dinitrate was able to improve survival of patients with heart failure ([@b16]). Shortly after it was demonstrated that angiotensin-converting enzyme (ACE) inhibitors could also improve survival ([@b42]; [@b29]). But the mortality remained high and the need for further improvement was evident. The failing human heart has an increased adrenergic drive, which mediates its adverse effect through beta1- and possibly beta2- and alpha1-adrenergic receptors ([@b9]). This was the rationale for introducing beta-blockers in the treatment of chronic heart failure.

Beta1-receptors are down-regulated in the failing heart; the beta2-receptors are un-changed and the alpha1-receptors are increased. In patients with heart failure it was found that 50% of the adrenergic receptors in the heart were beta1-receptors and the rest were beta2- and alpha1-receptors ([@b11], [@b13], [@b23]; [@b7]).

Most of the myocardial damage observed in heart failure appears to be beta1mediated ([@b21]) with both pathological hypertrophy ([@b32]) as well as apoptosis ([@b17]) being mediated via the beta1-receptor. Much myocardial damage in the failing human heart is mediated by norepinephrine (NE). The relative potency of NE for beta1-, beta2-, and alpha1-receptors is 20:1:2 ([@b8]). Norepinephrine is released from presynaptic stores and stimulates beta1-receptors preferentially ([@b28]).

On this background it is evident that beta-blockers can have a place in the treatment of heart failure, but it is unclear whether beta-1 selective blockers or non-selective blockers are preferable.

Beta-blocker treatment in heart failure
=======================================

Beta-blockers have been shown to be of clinical benefit in patients with chronic heart failure ([@b24]). The first study was performed by [@b49]). One patient was given alprenolol and 6 patients received practolol ([@b49]). They all had an improved ventricular function due to the beta-blocker treatment and considerations for using beta-blockers in the treatment of heart failure began.

During the nineties an array of large randomized trials of beta-blockers for the treatment of chronic heart failure (CHF) were conducted. In 1990 the results from the Xamoterol in Severe Heart Failure Trial was published ([@b52]). Even though preliminary data had shown that treatment with the beta1-blocker xamoterol in patients with CHF was a safe and effective treatment, the result of the trial was disappointing. No beneficial effect of treatment with xamoterol was observed. In an analysis of intention-to treat 9.1% of the patients in the xamoterol-treated group died within the first 100 days from randomization, compared with 3.7% in the placebo-treated group. Xamoterol has a major intrinsic sympatomimetic effect, which is not thought beneficial for use in patients with heart failure. The failure of xamoterol is generally attributed to the intrinsic sympatomimetic activity, but another important consideration is that the treatment was initiated with a high dose from the very start in patients with extreme risk.

In CIBIS I (The Cardiac Insufficiency Bisoprolol Study), bisoprolol was compared with placebo in 641 patients with CHF, New York Heart Association (NYHA) Classification III--IV, with a follow-up period of almost 2 years. No significant difference was seen in the rate of death ([@b15]), but the study was underpowered. A few years later bisoprolol was once again tested in the CIBIS II trial. 2647 patients were randomized to receive either bisoprolol or placebo, and the follow-up period lasted for about 1 year ([@b14]). This time a significant reduction in all cause mortality as well as cardiovascular death and hospitalization for cardiovascular reasons was observed. Actually the benefit in CIBIS I and II were identical and the differences in significance are explained by the different sample sizes of the studies.

The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) with 3991 patients enrolled, examined the effect of metoprolol in patients with CHF, NYHA II--IV, and as for bisoprolol, metoprolol succinate showed a favourable effect on all-cause mortality compared with placebo ([@b36]).

Another study was performed in a population with many black patients, where patients with CHF, NYHA III-IV were randomized to receive either bucindolol or placebo ([@b6]). A non-significant difference in all-cause mortality was observed, 15% of the patients in the group treated with bucindolol died compared with 17% in the group treated with placebo. The results of this trial have caused some debate. There have been speculations that the relative predominance of black patients influenced the results of the trial but this speculation has not been substantiated. In a subsequent retrospective study, it was demonstrated that there was a subset of patients who experienced marked sympatholysis with bucindolol ([@b12]) and who had an increased risk of death. There has also been an unresolved debate as to whether bucindolol is associated with intrinsic sympathomimetic activity ([@b3]; [@b34]). Should this be the case it might explain the failure of bucindolol similarly to the xamoterol trial described above.

Impressive results have been obtained with carvedilol. The results from the US Carvedilol Heart Failure Study were published in 1996. In this study 1064 patients with CHF were randomized to receive either carvedilol or placebo ([@b40]). The trial was designed to evaluate the safety of treatment with carvedilol and mortality was observed as a secondary f inding. As for the primary end point, a significant reduction in the risk of hospitalization was found and worsening of heart failure was reduced in the group treated with carvedilol. A risk reduction of 65% was found in favour of carvedilol. The problem with interpreting the results of this study was that it was stopped early and was a meta-analysis of a group of studies designed to demonstrate symptomatic relief of carvedilol. These problems became secondary with the study of carvedilol in patients with severe heart failure. The Carvedilol Prospective Randomized Cumulative Survival Study (COPERNICUS) trial was performed. 2289 patients with severe heart failure were randomized to receive carvedilol or placebo for a mean treatment period of 10.4 months ([@b41]). A decrease of 35% in risk of death was shown. The effect, previously seen in the group with mild or moderate heart failure, was thereby reproduced in patients with severe heart failure.

In the Carvedilol Post-Infarction Survival Control in LV Dysfunction (CAPRICORN) study, effect of carvedilol in patients who have had an acute myocardial infarction was investigated ([@b19]). Mean Left Ventricular Ejection Fraction (LVEF) was 32.8% and most of the patients were already treated with both ACE-inhibitors and diuretics. A 23% reduction in all-cause mortality was seen. This percentage in reduction is comparable with the results seen in the large trials on ACE-inhibitors after Acute Myocardial Infarction (AMI): SAVE (the Survival and Ventricular Enlargement trial), AIRE (the Acute Infarction Ramipril Efficacy study) and TRACE (the Trandolapril Cardiac Evaluation study) ([@b42]; [@b29]). In spite of the result it is debated whether CAPRICORN was a positive or a negative study. The initial primary endpoint of this study was all-cause mortality. During the trial the steering committee noted that all-cause mortality was lower than expected, and they changed the primary endpoint to the combination of all-cause mortality and all-cause hospitalization. Eventually the original endpoint came out positive and the new endpoint was neutral. To regulatory authorities, CAPRICORN was therefore a negative study, to a general scientific interpretation there are no specific rules and many consider the trial positive.

As a net result it is widely accepted that beta-blocker therapy has substantial benefit to patients with heart failure, with, and without myocardial infarction. One of many important questions that remain is whether different beta-blockers have different value.

The first developed beta-blockers, the so-called first generation beta-blockers, was a non-specific beta-blocker that blocks both beta1- and beta2-adrenoceptors. Propranolol, the traditionally used first-generation beta-blocker, is not recommended for use in heart failure patients: it has not been tested. Metoprolol and bisoprolol belongs to the group of second generation beta-blockers with a specific beta1-blockade. The third-generation beta-blockers include carvedilol and bucindolol and have a non-selective beta-blocking effect on both beta1- as well as beta2adrenoceptors. Carvedilol further has an alpha-blocking effect which results in a vasodilating property. Bucindolol also has a vasodilating property. The reason for the vasodilating property of bucindolol has not clearly been demonstrated, but it may be because of an intrinsic sympatomimetic effect. In addition to the adrenergic blocking properties carvedilol it has an antioxidant effect and suppresses endothelin biosynthesis ([@b51]; [@b38]; [@b33]; [@b4]).

The Carvedilol Or Metoprolol European Trial
===========================================

In The Carvedilol Or Metoprolol European Trial (COMET) two generations of beta-blockers were compared. Metoprolol, a second-generation beta-blocker was compared with the third-generation beta-blocker carvedilol ([@b43]). Both beta-blockers have been proven beneficial for use in a group of patients with heart failure ([@b40], [@b41]). The aim of the trial from the outset was to study whether the extra effects of carvedilol mattered clinically and therefore the trial was designed to ensure as close as possible beta-1 blocking effect in the two study groups.

3029 patients with CHF, mean ejection fraction 26%, and NYHA II--IV, were randomized to receive metoprolol tartrate with a target dose of 50mg twice daily or carvedilol with a target dose of 25mg twice daily. Both beta-blockers were well tolerated, and no differences were seen in terms of side-effects or withdrawals ([@b47]). A significant reduction in mortality was observed in favour of the group treated with carvedilol, with an absolute reduction in mortality of 5.7% over a 5 year follow-up period ([Figure 1](#fig1){ref-type="fig"}). Similarly to the reduction in mortality, a reduction in mortality due to cardiovascular reasons, stroke, sudden death, and death caused by circulatory failure was seen in the group treated with carvedilol. No differences were seen between the two groups as it comes to worsening in heart failure, hospitalizations, and cause-specific hospitalizations ([@b47]). As an interesting finding, carvedilol reduced the prevalence of new-onset diabetes by 22% compared with metoprolol ([@b46]). Mean duration of follow-up was 58 months, but the benefit, in concern of reduced mortality among the patients treated with carvedilol, appeared already at 6 months of observation.
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Much debate has been taking place since the COMET trial was first published. Criticism has been focused on the choice of formulation of metoprolol. In the COMET trial immediate-release (IR) metoprolol was used instead of the controlled-release (CR) metoprolol which was proven beneficial in the MERIT-HF trial ([@b36]). But when COMET was designed in 1996, the only clinical trial available was the Metoprolol in Dilated Cardiomyopathy (MDC) study ([@b48]). The question is then whether this formulation can improve mortality and is worthy of comparison with carvedilol. In the MDC trial, treatment with IR metoprolol in patients with idiopathic dilated cardiomyopathy resulted in a 34% reduction in primary end-point, which was of all-cause mortality or need for heart transplantation. Need for transplantation was used as an expression for deterioration of heart failure. No reduction in all-cause mortality was observed, possibly due to a very low number of deaths in the trial. But when follow up was extended a beneficial effect on mortality was indeed observed with IR metroprolol ([@b35]). The basic question is, whether the apparent superior effect on mortality seen with carvedilol compared with IR metoprolol, has any relevance to a higher dose and more sustained blockade that is obtained with 200mg of CR metoprolol as was used in MERIT-HF. Was there simply insufficient beta-1 blockade with IR metroprolol in the COMET study?

To assess the degree of beta1-blockade the most accepted method is to study exercise-induced increase in heart rate (HR). In a review of such studies it was found that a 20% reduction in exercise-induced tachycardia could be obtained with the dose of 50 mg, 100 mg and 150 mg daily with carvedilol, IR metoprolol, and CR metoprolol respectively ([@b39]). In the COMET trial no evaluation of the relative beta1-blockade of the two beta-blockers used was performed. The only information collected was the resting HR. A significant albeit small difference in the reduction of HR obtained was observed in the carvedilol arm, no difference in HR was seen beyond the f irst year of observation ([Figure 2](#fig2){ref-type="fig"}) ([@b39]). The CR metoprolol delivers 33% less metoprolol into the bloodstream than the IR metoprolol ([@b44]). A significantly higher beta1-blockade over 24 hours was seen with 200 mg of CR metoprolol than with IR metoprolol tartrate 50 mg × 3 ([@b2]). As carvedilol exert different adrenoceptor blocking properties besides its antioxidative effect, it is of interest to know which mechanism gives carvedilol its favorable effect in superiority to metoprolol on mortality.
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The alpha-blocking properties have been tested. Doxazosin, a selective alpha1-blocker, versus placebo was tested in 73 patients with CHF ([@b20]). Both investigators and patients assessment of symptomatic change was improved after treatment with doxazosin. When doxazosin was added to the beta1-blocker metoprolol in patients with heart failure, no improvement in hemodynamic measurements were seen, when compared with patients only treated with metoprolol ([@b30]). Even though carvedilol does not have the same pharmacokinetic properties as the combination of doxazosin and metoprolol, this study indicates that the beneficial effect seen with carvedilol is less likely to be caused solely by the alpha1-blocking properties of carvedilol.

The beta2-blocking effect affects the pre-synaptic release of NE, which reduces the amount of NE that can stimulate the beta1-receptors. carvedilol also exerts a more pronounced beta1-binding, and all together this reduces the deleterious effect of NE in heart failure ([@b9]).

Sub-studies from the COMET trial showed a decreased number of new-onset diabetes in the carvedilol arm, this sub-study is published as an abstract ([@b46]). This was in contrast to earlier findings from beta-blocker trials showing an increased number of new-onset diabetes when treated with traditional beta1-receptor blockers ([@b18]). That carvedilol might have a beneficial effects on the glucose metabolism was already shown in a study by [@b27]). In this study metoprolol was compared with carvedilol in a group of patients with hypertension. An improvement in insulin sensitivity was seen among those treated with carvedilol. [@b23]) also showed improved insulin sensitivity when treated with carvedilol. The changes were shown by making an insulin clamp testing.

Recently a large randomized trial in which the two beta-blockers were compared concerning their abilities in affecting the metabolic control in patients with diabetes and hypertension was published ([@b5]). An increase in glycosylated hemoglobin was seen in the metoprolol arm, whereas no change was seen in the carvedilol arm. Improvement in insulin sensitivity was seen in the carvedilol group and no change was seen among the patients treated with metoprolol.

This supports the findings from the COMET trial. In both trials the IR metoprolol was used. The beneficial role of carvedilol is speculated to be caused by its alpha-blocking properties and thereby causing vasodilation. Peripheral vasodilation facilitates glucose uptake in skeletal muscle and thereby improves insulin sensitivity ([@b45]). Other anti-hypertensives that also increase peripheral blood-flow have the same benef icial effect on insulin sensitivity ([@b31]).

Whether the increased peripheral blood-flow is solely to explain the benefit of carvedilol on insulin sensitivity is doubtful. The combined effect of carvedilol, including its antioxidative properties, is more likely to be the explanation.

Perspective of the COMET trial
==============================

The perspective of COMET can be divided in 3 parts: the importance of beta-1 inhibition, the importance of other effects of carvedilol and the clinical consequence.

Three beta-blockers with beta-1 activity have been shown to reduce mortality in CHF. One interpretation of COMET is that a more effective inhibition by carvedilol, either because of a higher dose being given or because carvedilol has a higher affinity for the beta-1 receptor, explained the marked difference. Thus effective beta-1 inhibition with as high a dose as possible is clearly important for the treatment of CHF.

The mortality difference in COMET was marked even though the difference in resting pulse was small. Therefore, it is likely that other effects of carvedilol compared with metoprolol are important for the treatment of heart failure. Further research is necessary to clarify whether beta-2 inhibition, alpha-1 inhibition, antioxidative properties of, inhibition of endothelin-1biosynthesis, or yet another effect is beneficial ([Table 1](#tbl1){ref-type="table"}).
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As for the clinical consequence at this time what remains is a continuing debate. carvedilol protagonists (including the authors of this paper) will claim that a superiority of carvedilol compared with metoprolol is likely and that this drug should therefore be preferred for the treatment of CHF. Metoprolol protagonists dismiss the results of COMET and insist that a high dose of ER metoprolol should serve equal benefit as carvedilol for patients with CHF.
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